Probing the requirements for dual angiotensin-converting enzyme C-domain selective/neprilysin inhibition

Lauren B. Arendse, Gyles Cozier, Charles Eyermann, Gregory Basarab, Sylva L U Schwager, Kelly Chibale, R Acharya, Edward D Sturrock

Research output: Contribution to journalArticlepeer-review

3 Citations (SciVal)
40 Downloads (Pure)


Selective inhibition of the angiotensin-converting enzyme C-domain (cACE) and neprilysin (NEP), leaving the ACE N-domain (nACE) free to degrade bradykinin and other peptides, has the potential to provide the potent antihypertensive and cardioprotective benefits observed for nonselective dual ACE/NEP inhibitors, such as omapatrilat, without the increased risk of adverse effects. We have synthesized three 1-carboxy-3-phenylpropyl dipeptide inhibitors with nanomolar potency based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan (LisW) to probe the structural requirements for potent dual cACE/NEP inhibition. Here we report the synthesis, enzyme kinetic data, and high-resolution crystal structures of these inhibitors bound to nACE and cACE, providing valuable insight into the factors driving potency and selectivity. Overall, these results highlight the importance of the interplay between the S1′ and S2′ subsites for ACE domain selectivity, providing guidance for future chemistry efforts toward the development of dual cACE/NEP inhibitors.
Original languageEnglish
Pages (from-to)3371-3387
Number of pages17
JournalJournal of Medicinal Chemistry
Issue number4
Early online date3 Feb 2022
Publication statusPublished - 24 Feb 2022

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Probing the requirements for dual angiotensin-converting enzyme C-domain selective/neprilysin inhibition'. Together they form a unique fingerprint.

Cite this